Biosimilars Market Demand, Growth, Opportunities, Analysis of Top Key Player and Forecast to 2025

1
Global Biosimilars Market

• Drivers, Restraints, Potential Growth
  Opportunities, Product Size, Application
  Estimation, Vendor Competitive Landscape, Trends
  and Forecast 2018-2025

Single Use License US 4500
Request Sample
2
Global Biosimilars Market

• The global biosimilars market size was
  anticipated to reach xx billion supported by a
  CAGR of xx over the forecast period. Occurrence
  of large number of chronic disorders and
  affordability of biosimilar drugs are the main
  factors participating in the growth of the global
  biosimilars market.
• Biosimilar products are similar to their
  accredited products on the basis of biological
  activity, efficacy, and safety and quality
  characteristics. An occurrence of chronic
  disorders such as cancer, anemia, diabetes,
  autoimmune diseases, kidney failure, rheumatoid
  arthritis, infectious diseases and deficiency of
  growth hormones is projected to fuel the global
  biosimilars industry in the coming years.
• Specialty biologics is the biggest factor for
  pharmaceutical cost growth in the market. In the
  U.S., as per research around nine patents for top
  20 retailing biologics are supposed to expire by
  2020. However, biosimilars are less expensive
  than the original drugs hence, more usage of
  biosimilars will lead to cost savings. The first
  biosimilar was accepted by European Medicines
  Agency in 2006 and has approved out of 40
  biosimilars.
• Food and Drug Administration (FDA) confirmed
  their first biosimilar through Zarxio, which is a
  biosimilar of filgrastim used in treating low
  blood neutrophils. Overall, total 11 biosimilars
  were approved by FDA out of which only 3
  biosimilars are launched.
• Browse the complete report on _at_
  https//www.adroitmarketresearch.com/industry-repo
  rts/biosimilars-market

3
Global Biosimilars Market

• Product segment in the biosimilars market
  consists of Erythropoietin, Human Growth Hormone,
  Insulin, Monoclonal Antibodies, Colony
  Stimulating Factors, Interferon and more.
  Biosimilars market is divided into oncology
  diseases, growth hormone deficiency, blood
  disorders, autoimmune and chronic disorders.
• Use of biosimilars in the treatment of blood
  disease is the maximum revenue making segment.
  Increase in use of biosimilars for treating
  several diseases is helping to scale up the
  global biosimilar market size.
• The biopharmaceutical industry is dependent on
  advanced technologies used in several processes
  of manufacturing and development. Some of the
  important technologies involved in biosimilars
  are Recombinant DNA technology, Monoclonal
  Antibodies Technology, Chromatography, Nuclear
  Magnetic Resonance Technology, Bioassay, Western
  Blotting, and Mass Spectrometry.
• Bioassay and Monoclonal Antibodies technology
  are the most important technologies used for
  validation and development of global biosimilars
  market share.
• Pharmaceutical companies are mainly focusing on
  development of biosimilars and they are accepting
  clinical trials strategies and approval.

4
Global Biosimilars Market

• Approval and clinical trials strategies are the
  main factors in the biosimilar market globally.
  Companies such as Merck Serono, Celltrion and
  Sandoz are looking for approvals across the
  world. These companies are branches of global
  industries such as Novartis and Merck, which
  allows investing in biosimilar market. 
• The plans accepted by manufacturers in an
  integrated manner where all clinical trials
  conducted for approvals and commercialization.
  Joint venture, License, product launch,
  partnership are the policies accepted by
  companies who had got permission from the
  authorities and have successfully copied the
  original drugs. Thus, development of biosimilars
  by manufacturers are increasing the growth of the
  global biosimilars industry.
• Benefits of the global biosimilars market
• Cost of treatment is less by using biosimilars
  rather than using the biological drug.
• The profit margin of operating original
  biological drug is around 30, but for operating,
  the biosimilar product, profit margin is around
  40.
• As license of original product expires thus,
  opportunities for a generic version of
  biopharmaceutical products is very large.
• Funding is easily available across the world.

5
Global Biosimilars Market

• Regional Overview
• Geographically, global biosimilar industry is
  divided into Europe, South America, North
  America, Asia Pacific and Middle East Africa.
  North America holds the largest share of the
  global biosimilar market. The market of North
  America is mainly driven due to the presence of
  research laboratories, such as Amgen, Sandoz,
  Teva Pharmaceuticals and many more. Due to the
  development of biotechnology companies, Asia
  Pacific is anticipated to experience growth over
  the forecast period.
• Key Players
• Companies involved in expanding the global
  biosimilar market size are Teva Pharmaceutical
  Industries Ltd., Amgen Inc., Sandoz
  International, Hoffmann-La Roche Ltd., Dr.
  Reddys Laboratories Ltd., Pfizer Inc., Mylan,
  Biocon, and Samsung Bioepis.
• Purchase a single user copy of the global
  Biosimilars market report _at_ https//www.adroitmark
  etresearch.com/researchreport/purchase/72

6
About Us

• Adroit Market Research is an India-based business
  analytics and consulting company. Our target
  audience is a wide range of corporations,
  manufacturing companies, product/technology
  development institutions and industry
  associations that require understanding of a
  markets size, key trends, participants and
  future outlook of an industry. We intend to
  become our clients knowledge partner and provide
  them with valuable market insights to help create
  opportunities that increase their revenues. We
  follow a code Explore, Learn and Transform. At
  our core, we are curious people who love to
  identify and understand industry patterns, create
  an insightful study around our findings and churn
  out money-making roadmaps. Our analysts have
  tracked high growth markets in chemicals
  materials, healthcare pharmaceuticals,
  semiconductor electronics, energy power, food
  retail, consumer goods, technology, and
  machinery equipment sectors across the world to
  identify new opportunities, potential customers,
  prepare go-to-market (GTM) strategies, identify
  segments for revenue growth for companies, and
  many more.

• US Headquarters3131 McKinney Ave Ste 600
  Dallas, TX 75204 ,U.S.A 

• Phone [phone]
• Email sales_at_adroitmarketresearch.com